ERROL SEGALL: Open Payments
NPI 1407855190 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,427 in 66 payments from 15 companies in 2025. Trend: 2023 $1,273 · 2024 $1,279 · 2025 $1,427
Food & beverage: $1,427
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $252 |
| Vanda Pharmaceuticals Inc. | 12 | $249 |
| Axsome Therapeutics, Inc. | 7 | $166 |
| Lundbeck LLC | 5 | $139 |
| Bausch Health US, LLC | 6 | $111 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| ABBVIE INC. | 4 | $70 |
| HARMONY BIOSCIENCES LLC | 2 | $67 |
| Corium, LLC | 3 | $60 |
Products named: REXULTI, Auvelity, FANAPT, HETLIOZ, APLENZIN, CAPLYTA, TRINTELLIX, VRAYLAR.
Industry payments across VA — which companies pay providers there.
